HERMES
Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with preserved ejection fraction and systemic inflammation
- Stage
- followup
- Medicine
- Ziltivekimab
- Population
- Hartfalen
- Phase
- III
- First Patient In
- 22 May 2023
- Last Patient In
- 30 September 2025
- Last Patient Last Visit
- 2 July 2027
National Lead
prof. dr. R.A. de Boer
Cardioloog
Study Director
dr. C.J.W. Borleffs
Cardioloog
Office Contact
